Literature DB >> 3891640

A tumor-associated antigen expressed in melanoma cells with lower malignant potential.

L Suter, J Brüggen, E B Bröcker, C Sorg.   

Abstract

The antigen K-1-2, detectable by a MAb is found in nevi and melanomas. It is associated with melanoma cells of low invasive and metastatic potential as shown by immunoperoxidase studies with cell lines, biopsies and autopsies: K-1-2 occurs in melanoma cell line SK-Mel 25, but not in cell line A-375. A-375 has a higher malignant potential than SK-Mel 25 because, in contrast to SK-Mel 25, it produces plasminogen activator and grows in nude mice. K-1-2 was frequently strongly expressed (greater than or equal to 50% cells positive) in flat (less than 1.5 mm) and less frequently in medium and thick primary tumors. In thick primary melanomas K-1-2 positive cells were confined to the junctional zone or to marginal, flat areas of the tumor. Only rarely does K-1-2 occur in metastases. Strong expression of the K-1-2 antigen was found less often in primary melanomas, which develop early metastases, than in tumors that had not metastasized during an observation period of 18 months. In 5 patients with disseminated metastatic disease, metastases strongly expressing K-1-2 and those negative for this marker or containing only a minor percentage of K-1-2 positive cells were observed simultaneously or at different times. These findings suggest that a change from high malignancy to low malignancy--as observed in animal systems--may also occur in human melanoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891640     DOI: 10.1002/ijc.2910350615

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.

Authors:  G N Van Muijen; L M Cornelissen; C F Jansen; C G Figdor; J P Johnson; E B Bröcker; D J Ruiter
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

2.  Modulation of melanoma-associated antigens by monoclonal antibodies as visualized by radioimmunoelectron microscopy and radioantibody binding assay.

Authors:  W Tilgen; S Matzku; I Kaufmann; M Engstner; J Brüggen; W Dippold; D Petzoldt
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  The relationship between characteristics of the tumor cells and sex of the patients in primary malignant melanomas.

Authors:  H Ostmeier; J Schumann; F Otto; V Krieg; B Fuchs; B Biess; G Burg; L Suter
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Metastatic human melanoma. Phenotypic heterogeneity and antigen expression in relation to the clinical status.

Authors:  L Suter; E B Bröcker; H Ostmeier; J Schumann; C Sorg
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines.

Authors:  K Rass; P Gutwein; C Welter; V Meineke; W Tilgen; J Reichrath
Journal:  Histochem J       Date:  2001-08

6.  Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro.

Authors:  K Krasagakis; C Garbe; J Eberle; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 7.  Radioimmunotherapy of malignancy using antibody targeted radionuclides.

Authors:  L M Cobb; J L Humm
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.